Patients w/ propensity to bleed (eg, due to recent trauma or surgery, active or recent GI bleeding or moderate hepatic impairment) or who are at increased risk of trauma. Concomitant administration of medicinal products that may increase the risk of bleeding (eg, NSAIDs, oral anticoagulants &/or fibrinolytics w/in 24-hr); antifibrinolytic therapy (aminocaproic acid or tranexamic acid) &/or recombinant factor VIIa. Discontinue 5 days prior to surgery if to undergo elective surgery & antiplatelet effect is not desired. History of MI w/ prior ischaemic stroke. Potential risk for bradyarrhythmia; patients at increased risk of bradycardic events (eg, patients w/o pacemaker w/ sick sinus syndrome, 2nd- or 3rd-degree AV block or bradycardic-related syncope). Discontinue use if new, prolonged or worsened dyspnoea occurs. Possible central sleep apnoea including Cheyne-Stokes respiration; may consider further clinical assessment if central sleep apnoea is suspected. Promptly treat patient if TTP occurs. False -ve platelet function test results for heparin-induced thrombocytopenia. Not recommended to be co-administered w/ high maintenance dose of ASA (>300 mg). Avoid premature discontinuation of treatment. May cause dizziness & confusion; observe caution while driving or using machines. Moderate hepatic impairment. Pregnancy. Not recommended during breastfeeding. Childn <18 yr.
Sign Out
